$900 per pill is less than sovaldi/harvoni. I'm sure someone will still complain as they want them to give it away!
Read the Street article says they took the low road by pricing lower than earlier drugs.
Gilead set the sticker price for the newly approved hepatitis C drug Epclusa at $74,760 for a 12 week course of treatment.
Should see some window dressing for 3rd Q as well. AMZN may be a candidate. Not so sure if AAPL will see much action since its been a big drip the whole year.
sorry, my bag. meant the 200 sma on the sp500. just hard to fathom that we fell that hard last 2 sessions.
watch 2020 on sp500. 50 sma Brexit was totally overdone but it cleaned the slate for new quarter. no more bellyaching about the s&p being over-valued I'd think.
BWLD very expensive restaurant stock. who'd have thought!
I don't think UK too impacted with immigration as is Germany but certainly plays a role. I think more impacted with neighboring countries like Italy/Greece/Portugal not pulling weight, I can't say I blame them,
I know this is crazy but it makes one wonder about the credibility of these analysts and their so-called price targets! Biotech companies are one of the few sectors that are making money in this economy. This political yo-yo game is well over-played. I keep waiting for some reasoning but have yet to see it.
excerpt....."It has come to our attention that the IPAB determination may be announced at Brookings on Thursday. The Independent Payment Advisory Board (IPAB) is an independent executive committee intended to contain Medicare spending growth by proposing CMS reforms to be implemented by the U.S. Department of Health and Human Services. The IPAB is “triggered” (comes into existence) when the actual growth rate exceeds a target growth rate set by the CMS actuary. Although IPAB can propose reforms to any portion of CMS spending, we do not believe that the IPAB will target Part D drug spending specifically."
In yahoo news on AMGN there is an article why biotech stocks got crushed. It relates to Medicare cutting drug costs but if you read the article it states this will not effect drug costs under Part D. Worth a read. Sounds like more scare tactics in the sector.
The sooner the ol gal stops yakkin the better
Nomura cut target from 125 to 115 but maintains buy recommendation. Nomura is probably in bed with Left.